Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (241-250 of 703) with videos related to

Pageof 71
Sort By:
British Journal of Cancer|August 18, 2018
Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosisChristoph Krisp, Robert Parker, Dana Pascovici, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatmentJames S Wilmott, Lauren E Haydu, Alexander M Menzies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III MelanomaJason Madore, Dario Strbenac, Ricardo Vilain, et al.
European Journal of Cancer Care|October 13, 2016
Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative studyR Liang, B Meiser, S Smith, et al.
Cancer|July 3, 2014
The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibitionMatthew M K Chan, Lauren E Haydu, Alexander M Menzies, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 25, 2016
Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cellsMary Jc Hendrix, Irawati Kandela, Andrew P Mazar, et al.
Melanoma Research|February 24, 2021
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trialsRoger Olofsson Bagge, Lars Ny, Paolo A Ascierto, et al.
Oncoimmunology|October 9, 2023
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapiesTuba N Gide, Elizabeth C Paver, Zarwa Yaseen, et al.
Frontiers in Oncology|May 2, 2022
Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNARussell J Diefenbach, Jenny H Lee, Ashleigh Stewart, et al.
Implementation Science Communications|October 1, 2022
Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science frameworkAndrea L Smith, Caroline G Watts, Michael Henderson, et al.
Pageof 71

Showing results (241-250 of 703) with videos related to

Sort By:
Pageof 71
British Journal of Cancer|August 18, 2018
Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosisChristoph Krisp, Robert Parker, Dana Pascovici, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatmentJames S Wilmott, Lauren E Haydu, Alexander M Menzies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III MelanomaJason Madore, Dario Strbenac, Ricardo Vilain, et al.
European Journal of Cancer Care|October 13, 2016
Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative studyR Liang, B Meiser, S Smith, et al.
Cancer|July 3, 2014
The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibitionMatthew M K Chan, Lauren E Haydu, Alexander M Menzies, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 25, 2016
Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cellsMary Jc Hendrix, Irawati Kandela, Andrew P Mazar, et al.
Melanoma Research|February 24, 2021
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trialsRoger Olofsson Bagge, Lars Ny, Paolo A Ascierto, et al.
Oncoimmunology|October 9, 2023
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapiesTuba N Gide, Elizabeth C Paver, Zarwa Yaseen, et al.
Frontiers in Oncology|May 2, 2022
Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNARussell J Diefenbach, Jenny H Lee, Ashleigh Stewart, et al.
Implementation Science Communications|October 1, 2022
Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science frameworkAndrea L Smith, Caroline G Watts, Michael Henderson, et al.
Pageof 71